Where do TCR therapies already have strong human evidence?
The strongest human evidence for T-cell receptor therapies is in blood cancers. Six different CAR T-cell products are now FDA-approved for six hematologic malignancies, including B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma [1]. In a large trial, CAR T cells improved 4-year overall survival in large B-cell lymphoma to 54.6% compared with 46.0% for standard chemotherapy followed by stem cell transplant — a meaningful gain for a hard-to-treat cancer [1]. For pediatric acute lymphoblastic leukemia, 48% of patients were alive and relapse-free at 3 years after CAR T therapy [1]. In multiple myeloma, CAR T cells extended progression-free survival to 13.3 months versus 4.4 months with standard therapy [1]. These are not small effects; they represent months to years of additional life for many patients.
Even in patients who relapse after one CAR T therapy, a second CAR T targeting a different antigen can still work. In a study of 61 children and young adults with B-cell acute lymphoblastic leukemia who received two different CAR T constructs, the second therapy achieved complete remission in 65.5% of patients, though this was lower than the 88.5% remission rate with the first therapy [4]. This shows that TCR-based therapies can be sequenced, but responses weaken with each round.
What about solid tumors — is the evidence strong enough?
For solid tumors, the human evidence is promising but still early and mixed. The most dramatic single case was a patient with metastatic pancreatic cancer who received a single infusion of T cells engineered to target a mutant KRAS G12D protein. The patient had a 72% reduction in visceral metastases, and the response was ongoing at 6 months [2]. This is remarkable because pancreatic cancer is notoriously resistant to immunotherapy. However, this is a single patient — not a trial — so it shows proof of concept, not proof of broad efficacy.
A larger phase I trial in 16 patients with various refractory solid cancers (including melanoma, sarcoma, and others) used a personalized approach: each patient received up to three different T-cell products engineered to target their own tumor mutations. The therapy was safe — only one patient had grade 1 cytokine release syndrome and one had grade 3 encephalitis — but the best response was stable disease in 5 patients, while 11 had disease progression [6]. The engineered T cells did reach the tumors, which is an important technical milestone, but the lack of tumor shrinkage in most patients shows that getting T cells into a solid tumor is not enough; they also need to function effectively in that hostile environment.
A comprehensive analysis of 174 registered clinical trials of TCR-T cell therapy found that the therapy shows significant efficacy across various tumor types, particularly in refractory hematologic malignancies and certain solid tumors, and that combining TCR-T with other immunotherapies enhanced the anti-tumor effects [5]. This suggests that combination approaches may be key for solid tumors.
What are the main limitations and risks that temper the hype?
TCR therapies come with significant toxicities that limit their use. Cytokine release syndrome — a systemic inflammatory response — occurs in approximately 40% to 95% of patients receiving CAR T cells, and neurologic disorders occur in about 15% to 65% [1]. These are usually reversible but can be severe. For T-cell-based therapies targeting solid tumors, a common adverse effect is capillary leak syndrome, where fluid leaks from blood vessels causing swelling, fluid in the lungs, and kidney problems [1].
Another major limitation is that responses are not durable for everyone. In the study of children receiving a second CAR T therapy after relapse, 72.5% of those who achieved complete remission eventually relapsed again [4]. This means that even when TCR therapies work, the cancer often finds a way to escape — for example, by losing the antigen that the T cells target.
The therapy is also complex and expensive to manufacture. The personalized approach used in the phase I trial required isolating each patient's tumor mutations, creating custom T-cell receptors, and engineering the cells — all at clinical grade [6]. This is not something that can be scaled easily or cheaply. However, research is underway to improve persistence and reduce doses: a modeling study using 'digital twins' of patients found that enriching the infused product with stem cell-like memory T cells could improve how long the engineered cells persist and might allow lower doses to be used [3].
About These Sources
This answer is built on 6 peer-reviewed studies — published from 2022 to 2024, 3 from 2024 or later, 5 in Q1 journals, collectively cited 955 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 62 papers retrieved from a database of over 500 million.
Sources used in this answer
CAR T Cells and T-Cell Therapies for Cancer
This review summarizes that six CAR T-cell products are FDA-approved for six hematologic malignancies, with improved overall survival in large B-cell lymphoma (54.6% vs 46.0% at 4 years) and progression-free survival in multiple myeloma (13.3 vs 4.4 months). No CAR T products are approved for solid tumors, but two other T-cell therapies gained approvals for melanoma and synovial cell sarcoma.
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
In a single patient with metastatic pancreatic cancer, a single infusion of TCR-engineered T cells targeting mutant KRAS G12D led to a 72% regression of visceral metastases, ongoing at 6 months. The engineered T cells persisted at >2% of circulating T cells at 6 months.
Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy
Using a quantitative systems pharmacology model and digital twins of patients from a clinical trial of TCR-engineered T cells for HPV-associated cancers, this study identified stem cell-like memory T cells (Tscm) as a key determinant of engineered T cell expansion and persistence, and predicted that enriching Tscm in the infused product could improve persistence and allow lower doses.
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
In a retrospective review of 61 children and young adults with B-ALL who received two different CAR T constructs, the second CAR T achieved complete remission in 65.5% of patients (vs 88.5% for the first), and 72.5% of responders eventually relapsed. Responses were better when the second CAR T targeted a different antigen than the first.
Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment
An analysis of 174 registered clinical trials of TCR-T cell therapy found significant efficacy across various tumor types, particularly in refractory hematologic malignancies and certain solid tumors, and that combining TCR-T with other immunotherapies enhanced anti-tumor effects.
Non-viral precision T cell receptor replacement for personalized cell therapy
In a first-in-human phase I trial, 16 patients with refractory solid cancers received up to three personalized neoTCR transgenic cell products manufactured using CRISPR-Cas9 non-viral genome editing. The therapy was safe; 5 patients had stable disease and 11 had progression. Engineered T cells were detected in tumor biopsies after infusion.